Amgen Inc (AMGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $251.89B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amgen Inc (AMGN) Stock Forecast
Analysts expect Amgen (AMGN) to earn $23.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $39.48B. Of 34 analysts, 12 rate the stock Buy or Strong Buy, 17 Hold and 5 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 25 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 34 ratings average 2.74, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 35% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 11.8% |
| Buy | 8 | 23.5% |
| Hold | 17 | 50.0% |
| Sell | 3 | 8.8% |
| Strong Sell | 2 | 5.9% |
- Consensus
- Hold
- Total analysts
- 34
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 6.4% and revenue estimates rise 4.6%.
- Fiscal year ending Dec 31, 2026
- $23.53
- EPS consensus, revenue $39.48B
- Fiscal year ending Dec 31, 2027
- $25.04
- EPS consensus, revenue $41.29B
- Next report
- Feb 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $23.53 | $22.97 to $25.79 | 32 | $39.48B | $38.88B to $39.73B | 29 |
| Dec 31, 2027 | $25.04 | $23.52 to $26.56 | 32 | $41.29B | $40.04B to $44.46B | 30 |
Quarterly Estimates
The EPS consensus falls from $5.72 for the quarter ending Dec 31, 2026 to $5.70 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.72 | $5.03 to $6.38 | 30 | $10.69B | $10.00B to $11.31B | 28 |
| Mar 31, 2027 | $5.70 | $5.13 to $6.09 | 10 | $9.48B | $8.78B to $10.07B | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 45 upward and 9 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 25 | 2 |
| Fiscal year ending Dec 31, 2027 | 17 | 5 |
| Quarter ending Mar 31, 2027 | 3 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.3% from $22.99.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $23.53 | $23.50 | $23.01 | $23.04 | $22.99 | +2.4% |
| Fiscal year ending Dec 31, 2027 | $25.04 | $24.99 | $24.51 | $24.40 | $24.28 | +3.1% |
| Quarter ending Mar 31, 2027 | $5.70 | $5.69 | $5.61 | $5.60 | $5.59 | +1.9% |
Frequently Asked Questions About AMGN
What is the AMGN stock forecast?
Consensus analyst estimates put Amgen's EPS at $23.53 for the fiscal year ending Dec 31, 2026, on revenue of $39.48B. The consensus rating from 34 analysts is Hold.
How do analysts rate AMGN stock?
Of 34 analysts covering Amgen, 4 rate it Strong Buy, 8 Buy, 17 Hold, 3 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from AMGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $23.53, with estimates from $22.97 to $25.79 from 32 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $25.04, with estimates from $23.52 to $26.56 from 32 analysts.
What revenue do analysts expect from Amgen next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $39.48B, with estimates from $38.88B to $39.73B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $41.29B, with estimates from $40.04B to $44.46B.
How many analysts cover AMGN?
34 analysts rate Amgen stock, and 32 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
AMGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts